Abstract��OBJECTIVE To advocate Patient Assistant Program Projects (PAP Projects) decision-making, this study assesses the long-term cost-effectiveness of 1-year adjuvant trastuzumab therapy for women with human epidermal growth factor receptor 2 (HER2) positive early breast cancer. METHODS A Markov model tracked yearly patients�� transitions between five health states. The cycle length was 1 year and the sum was 45. From the perspective of the China health insurance system, the direct medical cost was estimated based on a survey of clinical expert panels. A discounting rate of 3% was used to discount direct medical cost and health outcomes. Utility and transition probabilities were retrieved from the HERA trial and literature. To estimate the direct medical cost, a survey of clinical expert panels was conducted. The cost of trastuzumab and HER2 test based on Roche. The key factor of the model was realized by one-way sensitivity analysis. The result of a probability sensitivity analysis conducted by Monte Carlo simulation was expressed as an incremental cost-effectiveness scatter plot. RESULTS Without PAP Projects in Guangzhou, the adjuvant trastuzumab treatment prolonged 1.79 QALYs when the cost increased ��53 301 and the Incremental cost-effectiveness ratio (CER) was ��29 731/ QALY, which is cost-effective based on Guangzhou's per capita GDP in 2015. With PAP Projects, the adjuvant trastuzumab treatment was totally cost-effectiveness. The sensitivity analysis demonstrated that the model was moderate. CONCLUSION One year adjuvant trastuzumab treatment is a cost-effective therapy for patients with HER-2 positive breast cancer. With PAP Projects in Guangzhou, the adjuvant trastuzumab treatment is projected to be associated with improved QALYs and reduces direct medical costs, compared with the standard chemotherapy, represents a dominant treatment option among patients with HER2-Positive Early Breast Cancer. PAP Projects in Guangzhou should be persisted and spread in China.
TORRE L A, BRAY F, SIEGEL R L, et al. Global cancer statistics 2012[J]. CA Cancer J Clin, 2015, 65(2):87-108.
[2]
CHEN W, ZHENG R, BAADA P D, et al. Cancer statistics in China 2015[J]. CA Cancer J Clin, 2016, 66(2):115-132.
[3]
PORTER P. ��Westernizing�� women��s risks? Breast cancer in lower-income countries [J]. N Engl J Med,2008, 358(3):213-216.
[4]
WONG I O L, SCHOOLING C M, COWLING B J, et al. Breast cancer incidence and mortality in a transitioning Chinese population:current and future trends [J]. Br J Cancer, 2015, 112(1):167-170.
[5]
LIDGREN M, WILKING N, JONSSON B, et al. Cost-effectiveness of HER2 testing and trastuzumab therapy for metastatic breast cancer [J]. Acta Oncologica, 2008, 47(6):1018-1028.
[6]
CHUMSRI S, JETER S, JACOBS L K, et al. Pathologic complete response to preoperative sequential doxorubicin/cyclophosphamide and single-agent taxane with or without trastuzumab in stage ��/�� HER2-positive breast cancer [J]. Clin Breast Cancer, 2010, 10(1):40-45.
[7]
OSAKO T, NISHIMURA R, NISHIYAMA Y, et al. Pertuzumab for the treatment of patients with human epidermal growth factor receptor 2-positive breast cancer in Japan[J]. Mol Clin Oncol, 2015, 3(6):1268-1274.
[8]
GEYER C E, SCHWARTZ G, LINDQUIST D, et al.Lapatinib plus capecitabine for HER-2-positive advanced breast cancer[J].N Engl J Med, 2006,355(26):2733-2743.
[9]
MIRANDA R P,MARIN G R. Trastuzumab emtansine in locally advanced or metastatic HER2 positive breast cancer; GENESIS-SEFH drug evaluation report[J]. Farm Hosp,2015,39(3):171-175.
[10]
LI H, SHAO B, YAN Y, et al. Efficacy and safety of trastuzumab combined with chemotherapy for first-line treatment and beyond progression of HER2-overexpressing advanced breast cancer [J]. Chin J Cancer Res,2016, 28(3):330-338.
[11]
Biotech China. Tumor-targeted drugs on the market in China(��������ҩ�������й����������)[EB/OL]. [2016-04-07]. http://www. biovip. com/mednews/201604/33964. shtml.
[12]
Chinese Anti-Cancer Association Professional Committee of Breast Cancer. The guidelines and norms for Chinese anti-cancer association professional committee of breast cancer(2015 edition) [J]. China Oncology(�й�������־), 2015,25(9):692-754.
[13]
XI Y J,CAI Y H,JIN Y. Progress of research on the optimal treatment for patients with HER2-positive metastatic breast cancer[J]. Prog Mod Biomed(�ִ�����ҽѧ��չ),2015,15(35):6984-6989.
[14]
ZENG X H, PENGL B. Application of trastuzumab in HER2-positive early breast cancer [J]. Chin Pharm J(�й�ҩѧ��־), 2012, 47(20):1065-1068.
[15]
PICCART-GEBHART M J, PROCTER M, LEYLAND-JONES B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer[J]. N Engl J Med, 2005,353(16):1659-1672.
[16]
BELL R, GIANNI L, CAMERON D A, et al. Modelling predicts a long-term benefit from trastuzumab (Herceptin) use in HER2-positive breast cancer[Z]. Poster, 31st European Society for Medical Oncology(ESMO) Congress, Istanbul, Turkey, September 29-October 3, 2006.
[17]
National Bureau of Statistics, PRC. 2005 National population sampling survey database [EB/OL]. [2008-02-11]. http://www. stats. gov. cn/.
[18]
TENGS T O, WALLACE A. One thousand health-related-quality-of-life estimates[J]. Med Care, 2000, 38(6):583-537.
[19]
HAYMAN J A, HILLNER B E, HARRIS J R, et al. Cost-effectiveness of routine radiation therapy following conservative surgery for early-stage breast cancer[J]. J Clin Oncol, 1998, 16(3):1022-1029.
[20]
HILLNER B E, SMITH T J. Efficacy and cost effectiveness of adjuvant chemotherapy in women with node-negative breast cancer. A decision-analysis model[J]. N Engl J Med, 1991, 324(3):160-168.
[21]
CARTER K J, RITCHEY N P, CASTRO F, et al. Treatment of early-stage breast cancer in the elderly:a health-outcome-based approach[J]. Med Decis Making, 1998, 18(2):213-219.
[22]
ZHOU B F, Cooperative Meta-analysis Group of China Obesity Task Force. Predictive values of body mass index and waist circumference to risk factors of related diseases in Chinese adult population[J]. Biomed Environ Sci, 2002,23(1):5-10.
[23]
Research group of China Guidelines for Pharmacoeconomic Evaluations. China Guidelines for Pharmacoeconomic Evaluations(2011 edition)(�й�ҩ�ﾭ��ѧ����ָ��)[J/OL]. [2014-11-29]. http://www. ispor. org/PEguidelines/country-det. asp?c=28&t=4.
[24]
Statistics Bureau of Guangzhou Municipality. Statistical Communique on Guangzhou's 2015 National Economic and Social Development(2015������й��ú���ᷢչͳ�ƹ���) [EB/OL]. [2016-03-10]. http://www. gzstats. gov. cn/tjgb/.
[25]
MURRAY C J, EVANS D B, ACHARYA A, et al. Development of WHO guidelines on generalized cost-effectiveness analysis[J]. Health Econ, 2000, 9(3):235-251.
[26]
LIBERATO N L,MARCHETTI M,BAROSI G. Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer[J]. J Clin Oncol, 2007, 25(6):625-633.
[27]
PURMONEN T T, P?NK?L?INEN E, TURUNEN J H, et al. Short-course adjuvant trastuzumab therapy in early stage breast cancer in Finland:cost-effectiveness and value of information analysis based on the 5-year follow-up results of the FinHer Trial[J]. Acta Oncol, 2011, 50(3):344-352.
[28]
LANG H C, CHEN H W,CHIOU T J,et al. The real-world cost-effectiveness of adjuvant trastuzumab in HER-2/neu-positive early breast cancer in Taiwan[J]. J Med Econ, 2016:1-5.
[29]
CHEN W, JIANG Z, SHAO Z, et al. An economic evaluation of adjuvant trastuzumab therapy in HER2-positive early breast cancer[J]. Value Health, 2009,12(3):82-84.
2017, Vol. 52 
